Pinnacle West Asset Management Inc. Acquires 105 Shares of Becton, Dickinson and Company (NYSE:BDX)

Pinnacle West Asset Management Inc. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 5.0% in the third quarter, Holdings Channel reports. The firm owned 2,220 shares of the medical instruments supplier’s stock after purchasing an additional 105 shares during the period. Pinnacle West Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company during the third quarter worth about $26,000. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Opal Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $45,000. Abound Wealth Management lifted its stake in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC grew its holdings in Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Price Performance

NYSE BDX traded up $0.44 on Thursday, hitting $240.96. The stock had a trading volume of 174,178 shares, compared to its average volume of 1,378,861. The firm has a 50-day moving average of $237.33 and a 200-day moving average of $235.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23. The company has a market capitalization of $69.64 billion, a price-to-earnings ratio of 52.98, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter last year, the business posted $2.96 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.